Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 6 May, 2017 by The TZ Newswire Staff

Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?

Immunomedics watched its shares make a massive gain on Friday after the company announced the termination of its licensing deal with Seattle Genetics.

See also
- Next Article Meet Australia’s new most expensive mansion
- Previous Article Verizon Remains DJIA’s Worst Performing Stock for 2017
Editorial Calender

May 2017

M T W T F S S

1 2 3 4 5 6 7

8 9 10 11 12 13 14

15 16 17 18 19 20 21

22 23 24 25 26 27 28

29 30 31

« Apr Jun »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 6 May, 2017 by The TZ Newswire Staff

Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?

See also

Editorial Calender

Recent Tags